ATO together with all trans-retinoic acid (ATRA) has been shown to block several cancer-associated signaling pathways and eliminate tumor-initiating cells in TNBC by targeting peptidyl-prolyl isomerase (PIN1), an enzyme involved in various cellular processes that are aberrant in tumor cells [65]. The gene discussed is PIN1; the disease is neoplasm.